Diagnostic Role of Circulating Exosomal microRNA-1286 for the progression of Colorectal Cancer
Keywords:
miRNAs, colorectal carcinoma, CRC, Exosome, real-time PCR, Exosomal miRNAAbstract
OBJECTIVE: To assess the expression and clinical significance of exosomal miR-1286 for the detection and progression of CRC.
METHODOLOGY: miR-1286 was selected using the GEO dataset GSE39833. Bioinformatics tools were used to analyze its expression in CRC. After the collection of serum samples using the double centrifugation technique from 23 CRC patients, exosomal enrichment was performed, and miRNA extraction was done. After reverse transcription of the RNA template, its expression level was analyzed by qRT-PCR (Quantitative Reverse Transcription Polymerase Chain Reaction). miR-1286 expression levels correlated with colorectal cancer clinical characteristics, and patient survival was further examined using Kaplan-Meier analysis.
RESULTS: miRNA-1286 was found to be non-significant in comparing T3 and T4, N1 and N2 stages, and in discriminating colorectal metastatic tumor patients from non-metastatic tumor patients (p-value >0.05). ROC (Receiver Operating Characteristic) curve analysis revealed an AUC (Area under the Curve) of 0.69 with 75% sensitivity and 83.3% specificity at the cut-off value of > 1.07.
CONCLUSION: Upregulated expression of miR-1286 in colorectal cancer is not statistically significant enough to be used as a diagnostic biomarker for the detection and progression of CRC.
References
1- Matsuda T, Fujimoto A, Igarashi Y. Colorectal Cancer: Epidemiology, Risk Factors, and Public Health Strategies. Digestion. 2025.
2- Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. Cancer J Clinicians. 2022 Jul; 72(4): 372-401.
3- Khaliq SA, Fatima A, Siddiqui MG, Sheikh M, Zaib-Un-Nisa A. Point prevalence of colorectal cancer in a megacity of Pakistan, Karachi – A cross-sectional study. Univ J Pharmaceut Res. 2023 May 15.
4- Ibrar F, Atiq M, Shafqat F, Khan HM. Early-onset Colorectal Cancer and its association with its histological subtypes. Pak J Med Sci. 2024 Nov; 40(10): 2395.
5- Issa IA, Noureddine M. Colorectal cancer screening: An updated review of the available options. World J Gastroenterol. 2017 July 28; 23(28): 5086.
6- Ghafouri-Fard S, Hussen BM, Badrlou E, Abak A, Taheri M. MicroRNAs as important contributors in the pathogenesis of colorectal cancer. Biomed Pharmacother. 2021 August 1; 140: 111759.
7- Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021 Oct 1; 14(10): 101174.
8- Raj S, Kishor K, Devi S, Sinha DK, Madhawi R, Singh RK et al. Epidemiological trends of colorectal cancer cases in young population of Eastern India: A retrospective observational study. J Cancer Res Therapeut. 2023 May 25.
9- Boyle T, Fritschi L, Tabatabaei SM, Ringwald K, Heyworth JS. Smoking, alcohol, diabetes, obesity, socioeconomic status, and the risk of colorectal cancer in a population-based case–control study. Cancer Causes & Control. 2014 Dec; 25: 1659-68.
10- Sawicki T, Ruszkowska M, Danielewicz A, Nied?wiedzka E, Ar?ukowicz T, Przyby?owicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers. 2021 Apr 22; 13(9): 2025.
11- Lakemeyer L, Sander S, Wittau M, Henne-Bruns D, Kornmann M, Lemke J. Diagnostic and prognostic value of CEA and CA19-9 in colorectal cancer. Diseases. 2021 Mar 17; 9(1): 21.
12- Bresalier RS, Kopetz S, Brenner DE. Blood-based tests for colorectal cancer screening: do they threaten the Survival of the FIT test? Digestive Diseases and Sciences. 2015 Mar; 60: 664-71.
13- Zhang Y, Wang Y, Zhang B, Li P, Zhao Y. Methods and biomarkers for early detection, prediction, and diagnosis of colorectal cancer. Biomed Pharmacother. 2023 Jul 1; 163: 114786.
14- Holch JW, Demmer M, Lamersdorf C, Michl M, Schulz C, von Einem JC, Modest DP, Heinemann V. Pattern and dynamics of distant metastases in metastatic colorectal cancer. Visceral Medicine. 2017 Mar 14; 33(1): 70-5.
15- Zhou K, Liu M, Cao Y. New insight into microRNA functions in cancer: oncogene–microRNA–tumor suppressor gene network. Front Mol Biosci. 2017 Jul 7;4: 46.
16- Nors J, Iversen LH, Erichsen R, Gotschalck KA, Andersen CL. Incidence of recurrence and time to recurrence in stage I to III colorectal cancer: a nationwide Danish cohort study. JAMA Oncology. 2024 Jan 1; 10(1): 54-62.
17- Yaghoubi N, Avval FZ, Khazaei M, Aghaee-Bakhtiari SH. MicroRNAs as potential investigative and predictive biomarkers in colorectal cancer. Cellular Signalling. 2021 April 1; 80: 109910.
18- Mohamed SS, Ahmad A, Ab Mutalib NS, Tengku TA, Salleh MS, Zakaria AD et al. A panel of three MicroRNA signatures as a potential biomarker for CRC screening based on stages and functional prediction using bioinformatic analysis. Progress In Microbes & Molecular Biology. 2023 Aug 31; 6(1).
19- Alves dos Santos K, Clemente dos Santos IC, Santos Silva C, Gomes Ribeiro H, de Farias Domingos I, Nogueira Silbiger V. Circulating exosomal miRNAs as biomarkers for the diagnosis and prognosis of colorectal cancer. Int J Mol Sci. 2020 December 31; 22(1): 346.
20- Shi Y, Zhuang Y, Zhang J, Chen M, Wu S. Four circulating exosomal miRNAs as novel potential biomarkers for the early diagnosis of human colorectal cancer. Tissue and Cell. 2021 June 1; 70: 101499.
21- Sun K, Wang W, Zeng JJ, Wu CT, Lei ST, Li GX. MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma. Acta Pharmacologica Sinica. 2011 Mar; 32(3): 375-84.
22- Li H, Chai L, Ding Z, He H. CircCOL1A2 sponges MiR-1286 to promote cell invasion and migration of gastric cancer by elevating expression of USP10 to downregulate RFC2 ubiquitination level. J Microbiol Biotechnol. 2022 May 11; 32(7): 938.
23- Huang Z, Chen P, Jia R, Liu Y. Circ_0051079 functions as an oncogenic regulator in osteosarcoma by leading to MAFB expression upregulation by competitively interacting with miR-1286. J Orthop Surg Res. 2022 September 24;17(1): 428.
24- Tian M, Jiang M, Bi Y, Wang B. miR-1286, a Tumor Suppressor of Gastric Cancer, Serves as a Promising Biomarker for Screening Gastric Cancer from Gastritis. Biochemical Genetics. 2024 Oct; 62(5): 3761-73.
25- Li H, Lin X, Li C, Li J, Xu X, Meng D et al. MiR-1286 inhibits lung cancer growth through aerobic glycolysis by targeting PKM2. Arch Med Sci. 2019 September 18; 19(1): 151.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Journal of Liaquat University of Medical & Health Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Submission of a manuscript to the journal implies that all authors have read and agreed to the content of the undertaking form or the Terms and Conditions.
When an article is accepted for publication, the author(s) retain the copyright and are required to grant the publisher the right of first publication and other non-exclusive publishing rights to JLUMHS.
Articles published in the Journal of Liaquat University of Medical & health sciences are open access articles under a Creative Commons Attribution-Noncommercial - Share Alike 4.0 License. This license permits use, distribution and reproduction in any medium; provided the original work is properly cited and initial publication in this journal. This is in accordance with the BOAI definition of open access. In addition to that users are allowed to remix, tweak and build upon the work non-commercially as long as appropriate credit is given and the new creations are licensed under the identical terms. Or, in certain cases it can be stated that all articles and content there in are published under creative commons license unless stated otherwise.
